Mirati CEO David Meek departs; Charles Baum interim CEO; Q2 net loss $176.9M, KRAZATI rev $13.4M

Mirati Therapeutics, Inc.

CEO David Meek resigned Aug 7, 2023; founder Charles Baum named interim CEO; Meek remains consultant through Oct 15.
Q2 net loss $176.9M ($3.04/sh); KRAZATI revenue $13.4M; cash $779.4M; FY23 net cash burn guidance $560-580M.
Plans Phase 3 adagrasib + pembro in 1L NSCLC TPS≥50% by year-end; CHMP issued negative opinion on conditional MAA.
MRTX1719 initial data show favorable safety and early activity in MTAP-deleted cancers; Phase 2 planned H1 2024.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

David Meek

Chief Executive Officer

Mirati Therapeutics, Inc.

Effective: 2023-08-07
Successor: Charles M. Baum
Filed: August 8, 2023, 7:59 PM ET

On August 7, 2023 (the “Meek Separation Date”), David Meek resigned as a member of the Company’s board of directors and as the Company’s Chief Executive Officer and principal executive officer.

Appointed (interim)

Charles M. Baum

Interim Chief Executive Officer

Mirati Therapeutics, Inc.

Effective: 2023-08-07
Filed: August 8, 2023, 7:59 PM ET

The Company’s board of directors has, effective as of the Meek Separation Date, appointed Charles M. Baum, M.D., Ph.D., in addition to his other titles, as Interim Chief Executive Officer of the Company and as the Company’s principal executive officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mirati Therapeutics, Inc. reported financial results for second quarter 2023.

Period: second quarter 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Mirati Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Meek resigned as Chief Executive Officer at Mirati Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On August 7, 2023 (the “Meek Separation Date”), David Meek resigned as a member of the Company’s board of directors and as the Company’s Chief Executive Officer and principal executive officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles M. Baum was appointed as Interim Chief Executive Officer at Mirati Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

The Company’s board of directors has, effective as of the Meek Separation Date, appointed Charles M. Baum, M.D., Ph.D., in addition to his other titles, as Interim Chief Executive Officer of the Company and as the Company’s principal executive officer.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-23-206176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.